Inhibrx Biosciences Inc.(INBX)

Biotechnology · La Jolla, CA

$95.15+0.59 (+0.62%)

Delayed quote: Oct 6, 2026, 10:10 AM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T14:12:23.377Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:12:23.377Z.

Quote observation: 2026-10-06T14:10:14.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -125,604,000
Quote market capitalization: 1,395,963,348
Total debt · period ending 2026-06-30: 5,341,000
Cash · period ending 2026-06-30: 133,344,000

FMP input reference: 771dc6670e9772695969b0bf6104b917a4d7f40f340cdb77ec2424dd20cacd43

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

INBX EBITDA Yield Metrics

EBITDA YIELD

N/A

INBX Competitors' EBITDA Yield

INBX

Inhibrx Biosciences Inc.

Current

Market Cap

$1.40B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KLRA

Kailera Therapeutics, Inc.

vs INBX

Market Cap

$1.35B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANAB

AnaptysBio, Inc.

vs INBX

Market Cap

$1.43B

EBITDA Yield

8.69%

TTM Avg

3.11%

3Y Avg

3.11%

5Y Avg

3.25%

COAG

Hemab Therapeutics Holdings, Inc. Common Stock

vs INBX

Market Cap

$1.34B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MAZE

Maze Therapeutics, Inc.

vs INBX

Market Cap

$1.45B

EBITDA Yield

N/A

TTM Avg

19.73%

3Y Avg

19.73%

5Y Avg

19.73%

HCSG

Healthcare Services Group, Inc.

vs INBX

Market Cap

$1.47B

EBITDA Yield

11.06%

TTM Avg

6.15%

3Y Avg

7.10%

5Y Avg

6.61%

DRTS

Alpha Tau Medical Ltd

vs INBX

Market Cap

$1.32B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVBP

ArriVent BioPharma, Inc.

vs INBX

Market Cap

$1.33B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BRVE

Braveheart Bio, Inc.

vs INBX

Market Cap

$1.46B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GHRS

GH Research PLC

vs INBX

Market Cap

$1.49B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Inhibrx Biosciences Inc. (INBX)	$1.40B	N/A	N/A	N/A	N/A
Kailera Therapeutics, Inc. (KLRA)vs ›	$1.35B	N/A	N/A	N/A	N/A
AnaptysBio, Inc. (ANAB)vs ›	$1.43B	8.69%	3.11%	3.11%	3.25%
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.34B	N/A	N/A	N/A	N/A
Maze Therapeutics, Inc. (MAZE)vs ›	$1.45B	N/A	19.73%	19.73%	19.73%
Healthcare Services Group, Inc. (HCSG)vs ›	$1.47B	11.06%	6.15%	7.10%	6.61%
Alpha Tau Medical Ltd (DRTS)vs ›	$1.32B	N/A	N/A	N/A	N/A
ArriVent BioPharma, Inc. (AVBP)vs ›	$1.33B	N/A	N/A	N/A	N/A
Braveheart Bio, Inc. (BRVE)vs ›	$1.46B	N/A	N/A	N/A	N/A
GH Research PLC (GHRS)vs ›	$1.49B	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

INBX EBITDA Yield Metrics

INBX Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics